Cite
Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease.
MLA
Hammond, Jacob B., et al. “Gauging the Efficacy of Neoadjuvant Endocrine Therapy in Breast Cancer Patients with Known Axillary Disease.” Journal of Surgical Oncology, vol. 122, no. 4, Sept. 2020, pp. 619–22. EBSCOhost, https://doi.org/10.1002/jso.26047.
APA
Hammond, J. B., Parnall, T. H., Scott, D. W., Kosiorek, H. E., Pockaj, B. A., Ernst, B. J., Northfelt, D. W., McCullough, A. E., Ocal, I. T., & Cronin, P. A. (2020). Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease. Journal of Surgical Oncology, 122(4), 619–622. https://doi.org/10.1002/jso.26047
Chicago
Hammond, Jacob B., Taylor H. Parnall, Derek W. Scott, Heidi E. Kosiorek, Barbara A. Pockaj, Brenda J. Ernst, Donald W. Northfelt, Ann E. McCullough, Idris Tolgay Ocal, and Patricia A. Cronin. 2020. “Gauging the Efficacy of Neoadjuvant Endocrine Therapy in Breast Cancer Patients with Known Axillary Disease.” Journal of Surgical Oncology 122 (4): 619–22. doi:10.1002/jso.26047.